National

Per the WSJ: the EpiPen rival Auvi-Q from Kaleo is set to reenter the market next month after a recall last year due to manufacturing issues. The list price is way higher than the EpiPen — but the company claims it will put a program in place to make sure no one pays more than $360 out of pocket, and many won't pay anything at all.

Auvi-Q price: $4,500 ($360 after discount)

EpiPen rival injects itself into market

The new competitor is expensive, but its maker is promising discounts

Health Care

Pharmaceuticals

<a class="gtmContentClick" data-vars-link-text="Per the WSJ" data-vars-click-url="http://www.wsj.com/articles/rival-to-epipen-allergy-treatment-to-return-to-market-1484855236" data-vars-content-id="ccdba4b4-f3fd-46a5-88b3-817b9355fb07" data-vars-headline="EpiPen rival injects itself into market" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="http://www.wsj.com/articles/rival-to-epipen-allergy-treatment-to-return-to-market-1484855236" target="_blank">Per the WSJ</a>: the EpiPen rival Auvi-Q from Kaleo is set to reenter the market next month after a recall last year due to manufacturing issues. The list price is way higher than the EpiPen — but the company claims it will put a program in place to make sure no one pays more than $360 out of pocket, and many won&#x27;t pay anything at all.EpiPen price: $609Auvi-Q price: $4,500 ($360 after discount)

EpiPen rival injects itself into market

Go deeper